Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-1440
    Keywords: Breast cancer ; Immune complexes
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary In 68 patients with metastatic breast cancer a follow-up study was performed to correlate circulating immune complexes (CIC) as detected by the C1q binding assay and the Raji cell radio immunoassay with the state of disease. Clinical examinations and determinations of CIC were carried out all four to eight weeks over at least six months. 19 patients were positive for CIC in the C1q binding assay and 12 in the Raji cell radio-immunoassay. There was no correlation between the results of both tests. In comparison 26 patients out of 68 with rheumatoid arthritis were positive in the C1q binding assay and 32 in the Raji cell assay. In these patients the results of both tests correlated significantly. There was only in a few cases of metastatic breast cancer a positive correlation between levels of CIC and changes of tumor burden. Furthermore, CIC did not prove to be of prognostic value.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 64 (1986), S. 701-707 
    ISSN: 1432-1440
    Keywords: Carcinoembryonic antigen ; CEA ; Breast cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The diagnostic validity of serial CEA determinations in metastatic breast cancer was investigated. First, the CEA values within 8 weeks after start of therapy were correlated with the response to therapy. Second, the CEA levels were used to predict progression after remission or stable disease. These investigations were performed in 150 patients with advanced breast cancer who had clinical follow-ups and serial CEA determinations every one to three months. CEA was not useful for monitoring response to therapy (sensitivity 63%, specifity 58%) or prediction of relapse (sensitivity 61%, specifity 82%) if CEA levels were correlated with clinical course in all patients. However, diagnostic validity of CEA was achieved if the patients were selected and appropriate definitions of significant changes in CEA used. Thus, 83% of the responders (sensitivity) could be identified by a significant decrease of CEA titers in patients with CEA levels of ≧10 ng/ml. A decrease of more than 10% of pretreatment levels during the first 4–8 weeks after start of therapy proved to be the appropriate definition of a significant decrease of CEA titers. However, 32% of the non-responders were misclassified as responders (unspecifity) using these criteria. The positive predictive value of a significant decrease of CEA for response to therapy was 72% (prevalence 45%), the negative predictive value 82% (prevalence 55%). Rising CEA titers specifically predicted progression of disease in patients with remission or stable disease. However, an appropriate sensitivity (86%) was achieved only in patients with baseline CEA levels of ≧5 ng/ml. The selection criteria described applied to one-third of the patients in the present study. Prospective studies based on these results have to show whether the definitions used can be generalized and are to be recommended for clinical practice.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Journal of cancer research and clinical oncology 108 (1984), S. 341-344 
    ISSN: 1432-1335
    Keywords: CEA ; Breast cancer ; Prognosis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The capability of breast cancer to secrete CEA might have biological significance. In 105 patients with metastatic breast cancer serial CEA determinations and clinical follow-up data were available during progression of disease up to death. In this series, 39 patients (37%) had constantly low CEA levels (〈10 ng/ml), whereas 66 patients (63%) showed CEA values exceeding 10 ng/ml with progression. The patients with low CEA levels had significantly shorter median survival times (P=0.001) after mastectomy (39 versus 65 months) and after recurrence (18 versus 28 months) than the patients with high CEA levels. This difference was due first to a poor-risk group of 13 patients with rapidly disseminating tumors, very short survival (〈12 months), and low CEA levels. Secondly, there were more patients with pulmonary involvement and unfavorable prognosis and fewer patients with osseous metastases and long survival in the low-CEA group. In conclusion, there might be a subtype of breast cancer with rapid progression and low CEA secretion. This clinical observation has to be confirmed by histological grading and CEA staining of these tumors.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...